Point and interval estimation in two-stage adaptive designs with time to event data and biomarker-driven subpopulation selection
暂无分享,去创建一个
Nigel Stallard | Susan Todd | Ekkehard Glimm | Peter K Kimani | Lindsay A Renfro | Josephine N Khan | John A Kairalla | S. Todd | J. Khan | E. Glimm | N. Stallard | P. Kimani | J. Kairalla | L. Renfro
[1] Gernot Wassmer,et al. Designing Issues in Confirmatory Adaptive Population Enrichment Trials , 2015, Journal of biopharmaceutical statistics.
[2] Werner Brannath,et al. Shrinkage estimation in two‐stage adaptive designs with midtrial treatment selection , 2013, Statistics in medicine.
[3] H. Schäfer,et al. Modification of the sample size and the schedule of interim analyses in survival trials based on data inspections , 2001, Statistics in medicine.
[4] K. Gabriel,et al. On closed testing procedures with special reference to ordered analysis of variance , 1976 .
[5] Jiunn T. Hwang. EMPIRICAL BAYES ESTIMATION FOR THE MEANS OF THE SELECTED POPULATIONS , 2016 .
[6] KyungMann Kim. Group Sequential Methods with Applications to Clinical Trials , 2001 .
[7] Harold B. Sackrowitz,et al. Two stage conditionally unbiased estimators of the selected mean , 1989 .
[8] Martin Posch,et al. Design and estimation in clinical trials with subpopulation selection , 2018, Statistics in medicine.
[9] Gernot Wassmer,et al. Planning and Analyzing Adaptive Group Sequential Survival Trials , 2006, Biometrical journal. Biometrische Zeitschrift.
[10] John Whitehead. One-stage and two-stage designs for phase II clinical trials with survival endpoints. , 2014, Statistics in medicine.
[11] Anastasios A. Tsiatis,et al. The asymptotic joint distribution of the efficient scores test for the proportional hazards model calculated over time , 1981 .
[12] Anastasios A. Tsiatis,et al. Sequential methods for parametric survival models , 1995 .
[13] Nigel Stallard,et al. A comparison of methods for constructing confidence intervals after phase II/III clinical trials , 2014, Biometrical journal. Biometrische Zeitschrift.
[14] Nigel Stallard,et al. Estimation after subpopulation selection in adaptive seamless trials , 2015, Statistics in medicine.
[15] M. Kieser,et al. Point estimation in adaptive enrichment designs , 2017, Statistics in medicine.
[16] Nigel Stallard,et al. Point estimation following two‐stage adaptive threshold enrichment clinical trials , 2018, Statistics in medicine.
[17] Nigel Stallard,et al. Uniformly minimum variance conditionally unbiased estimation in multi-arm multi-stage clinical trials , 2018 .
[18] D Magirr,et al. Simultaneous confidence intervals that are compatible with closed testing in adaptive designs , 2013, Biometrika.
[19] Werner Brannath,et al. A new class of powerful and informative simultaneous confidence intervals , 2014, Statistics in medicine.
[20] W. Lehmacher,et al. Adaptive Sample Size Calculations in Group Sequential Trials , 1999, Biometrics.
[21] Jenny Y. Zhang,et al. Statistical design for a confirmatory trial with a continuous predictive biomarker: A case study. , 2017, Contemporary clinical trials.
[22] John Whitehead,et al. On the bias of maximum likelihood estimation following a sequential test , 1986 .
[23] Martin Posch,et al. Nested combination tests with a time‐to‐event endpoint using a short‐term endpoint for design adaptations , 2019, Pharmaceutical statistics.
[24] P. Bauer,et al. Modification of the sample size and the schedule of interim analyses in survival trials based on data inspections by H. Schäfer and H.‐H. Müller, Statistics in Medicine 2001; 20: 3741–3751 , 2004, Statistics in medicine.
[25] Jack Bowden,et al. Unbiased Estimation of Selected Treatment Means in Two‐Stage Trials , 2008, Biometrical journal. Biometrische Zeitschrift.
[26] Michael Rosenblum. Confidence intervals for the selected population in randomized trials that adapt the population enrolled. , 2013, Biometrical journal. Biometrische Zeitschrift.
[27] Bart Spiessens,et al. Adjusted significance levels for subgroup analyses in clinical trials. , 2010, Contemporary clinical trials.
[28] Nigel Stallard,et al. Point estimates and confidence regions for sequential trials involving selection , 2005 .
[29] Xiaoyun Li,et al. Estimation of treatment effect in two‐stage confirmatory oncology trials of personalized medicines , 2017, Statistics in medicine.
[30] Daniel J Sargent,et al. Adaptive randomized phase II design for biomarker threshold selection and independent evaluation. , 2014, Chinese clinical oncology.
[31] James M. Robins,et al. Semiparametric Efficiency and its Implication on the Design and Analysis of Group-Sequential Studies , 1997 .
[32] H Merabet,et al. The design and analysis of sequential clinical trials , 2013 .
[33] Jack Bowden,et al. Accounting for selection and correlation in the analysis of two-stage genome-wide association studies , 2016, Biostatistics.
[34] N. Simon,et al. Adaptive enrichment designs for clinical trials. , 2013, Biostatistics.
[35] Nigel Stallard,et al. Group-Sequential Methods for Adaptive Seamless Phase II/III Clinical Trials , 2011, Journal of biopharmaceutical statistics.
[36] Jack Bowden,et al. Conditionally unbiased and near unbiased estimation of the selected treatment mean for multistage drop-the-losers trials , 2013, Biometrical journal. Biometrische Zeitschrift.
[37] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .
[38] Tim Friede,et al. Flexible selection of a single treatment incorporating short‐term endpoint information in a phase II/III clinical trial , 2015, Statistics in medicine.
[39] Nigel Stallard,et al. Conditionally unbiased estimation in phase II/III clinical trials with early stopping for futility , 2013, Statistics in medicine.
[40] K. Ballman,et al. Biomarker: Predictive or Prognostic? , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] Julie M Gastier-Foster,et al. Improved Survival for Children and Young Adults With T-Lineage Acute Lymphoblastic Leukemia: Results From the Children's Oncology Group AALL0434 Methotrexate Randomization. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] Lindsay A. Renfro,et al. A Randomized, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Monotherapy Ontuxizumab (MORAb-004) Plus Best Supportive Care in Patients with Chemorefractory Metastatic Colorectal Cancer , 2017, Clinical Cancer Research.
[43] Thomas Jaki,et al. Estimation in multi‐arm two‐stage trials with treatment selection and time‐to‐event endpoint , 2017, Statistics in medicine.
[44] Christopher Jennison,et al. Group Sequential Analysis Incorporating Covariate Information , 1997 .
[45] Frank Bretz,et al. Confirmatory adaptive designs with Bayesian decision tools for a targeted therapy in oncology , 2009, Statistics in medicine.
[46] W. D. Ray. 4. Modelling Survival Data in Medical Research , 1995 .
[47] Jack Bowden,et al. Unbiased estimation in seamless phase II/III trials with unequal treatment effect variances and hypothesis‐driven selection rules , 2016, Statistics in medicine.
[48] C. Jennison,et al. An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints † , 2011, Pharmaceutical statistics.